Mitraclip insertion to hasten recovery from severe COVID-19 disease
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected 188 countries worldwide with a global death toll of over a million.1 The severe form of the disease is more commonly seen in the elderly and patients with multiple comorbiditie...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14676
- Acceso en línea:
- https://doi.org/10.1016/j.case.2020.10.004
http://hdl.handle.net/20.500.12010/14676
- Palabra clave:
- COVID-19 disease
Mitraclip insertion
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)
| Summary: | The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected 188 countries worldwide with a global death toll of over a million.1 The severe form of the disease is more commonly seen in the elderly and patients with multiple comorbidities and carries a bad prognosis.1, 2 Patients with valvular heart disease are also at an increased risk of adverse outcomes from COVID-19.3 MitraClip (Abbott Vascular, Santa Clara, California) has been approved for functional as well as degenerative mitral regurgitation in the USA.4-8 We describe a case of 67 year old gentleman with severe COVID-19 infection with multiple complications who underwent MitraClip implantation (Abbott Vascular, Santa Clara, California) to treat with refractory pulmonary edema to hasten recovery from this lethal disease. |
|---|